A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Veröffentlicht vonadmin 27. Juli 2020 Dittrich, C, Fridrik, MA, Koenigsberg, R, Lee, C, Goeldner, R, Hilbert, J, Greil, R. http://www.ncbi.nlm.nih.gov/pubmed/25529193